PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

December 15, 2022

https://www.globenewswire.com/news-release/2022/12/15/2574493/37149/en/PDS-Biotech-Completes-First-Stage-of-Enrollment-in-Checkpoint-Inhibitor-Refractory-Arm-of-Phase-2-Clinical-Trial-in-Advanced-HPV16-Positive-Head-and-Neck-Cancer.html

FLORHAM PARK, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced the completion of enrollment in the first stage of the checkpoint inhibitor refractory group of its VERSATILE-002 Phase 2 study for the potential treatment of recurrent and/or metastatic human papillomavirus (HPV16)-positive head and neck cancer. 90% of HPV-associated head and neck cancers in the US are reported to be caused by HPV16, as reported in a study published in the Journal of Clinical Medicine.

Read more at globenewswire.com

Related news for (PDSB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.